VCN Biosciences Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 10

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 2

VCN Biosciences General Information

Description

Developer of pharmaceuticals dedicated to discovering new therapeutic approaches for tumors that lack effective treatment. The company uses an oncolytic adenovirus technology platform to design agents that replicate and self-amplify exclusively in tumor cells, thereby helping healthcare institutes with the treatment of refractory tumors such as pancreatic adenocarcinomas.

Contact Information

Website
www.vcnbiosciences.com
Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Acquirer
Theriva Biologics
Primary Office
  • Avinguda de la Generalitat, 152
  • Sant Cugat del Vallès
  • 08174 Barcelona
  • Spain

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

VCN Biosciences Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore VCN Biosciences‘s full profile, request access.

Request a free trial

VCN Biosciences Patents

  • 8

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 1

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

VCN Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2016257196-A1 Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment Active 04-May-2015 0000000000
AU-2016257196-B2 Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment Active 04-May-2015 0000000000
CA-2985029-A1 Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment Pending 04-May-2015 0000000000
EP-3292142-A1 Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment Pending 04-May-2015 0000000000
JP-2018519847-A Oncolytic adenoviruses with mutations in immunodominant adenovirus epitopes and their use in cancer treatment Active 04-May-2015 A61K35/761 0
To view VCN Biosciences’s complete patent history, request access »

VCN Biosciences Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

VCN Biosciences Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore VCN Biosciences‘s full profile, request access.

Request a free trial